Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 230,200 | 569,500 | 411,000 | 269,600 | 143,000 |
| Depreciation Amortization | 21,100 | 71,200 | 52,100 | 33,900 | 15,900 |
| Income taxes - deferred | 36,600 | -37,400 | -2,600 | 200 | 200 |
| Accounts receivable | -81,500 | -60,400 | -54,800 | -64,700 | -32,200 |
| Other Working Capital | -175,300 | 99,500 | 51,400 | -500 | -56,200 |
| Other Operating Activity | 97,200 | 62,000 | 46,200 | 58,900 | 36,400 |
| Operating Cash Flow | $128,300 | $704,400 | $503,300 | $297,400 | $107,100 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -4,400 | -9,800 | -6,500 | -112,400 | 98,500 |
| PPE Investments | -15,900 | -176,100 | -112,900 | -64,800 | -27,700 |
| Net Acquisitions | -82,000 | N/A | N/A | N/A | N/A |
| Purchase Of Investment | -167,200 | -1,072,700 | -921,700 | -174,800 | -75,400 |
| Sale Of Investment | 422,800 | 1,087,000 | 789,800 | 92,800 | 47,700 |
| Purchase Sale Intangibles | -2,700 | -41,300 | -41,300 | -41,100 | N/A |
| Other Investing Activity | -2,100 | -40,100 | -40,600 | -36,600 | 4,200 |
| Investing Cash Flow | $151,200 | $-211,700 | $-291,900 | $-295,800 | $47,300 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 377,400 | 253,500 | 24,600 | 15,900 | 9,700 |
| Debt Repayment | -353,400 | -31,400 | -25,700 | -19,300 | -9,500 |
| Common Stock Issued | 23,100 | 103,300 | 82,700 | 44,600 | 19,500 |
| Common Stock Repurchased | -437,400 | -662,300 | -380,900 | -380,700 | -344,100 |
| Other Financing Activity | -1,000 | 68,400 | 25,700 | 2,100 | -44,700 |
| Financing Cash Flow | $-391,300 | $-268,500 | $-273,600 | $-337,400 | $-369,100 |
| Exchange Rate Effect | 1,000 | -12,500 | -11,200 | -12,700 | -2,300 |
| Beginning Cash Position | 930,100 | 718,400 | 718,400 | 718,400 | 718,400 |
| End Cash Position | 819,300 | 930,100 | 645,000 | 369,900 | 501,400 |
| Net Cash Flow | $-110,800 | $211,700 | $-73,400 | $-348,500 | $-217,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 128,300 | 704,400 | 503,300 | 297,400 | 107,100 |
| Capital Expenditure | -15,900 | -176,100 | -112,900 | -64,800 | -27,700 |
| Free Cash Flow | 112,400 | 528,300 | 390,400 | 232,600 | 79,400 |